Kirby McInerney LLP is investigating potential claims against the Board of Directors of Chelsea Therapeutics International, Ltd. (“Chelsea Therapeutics” or the “Company”) (NASDAQ: CHTP) concerning the proposed acquisition of the Company by H. Lundbeck A/S (“Lundbeck”). Under the terms of the definitive merger agreement, Chelsea Therapeutics stockholders will receive $6.44 in cash and up to $1.50 in Contingent Value Rights for each share of Chelsea Therapeutics owned, representing a total potential consideration of up to $658 million. The investigation concerns whether the Chelsea Therapeutics Board of Directors violated its fiduciary duties by agreeing to the proposed transaction and whether the proposed consideration adequately values Chelsea Therapeutics’ common stock. If you are a Chelsea Therapeutics stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at email@example.com, by telephone at (212) 699-1145 or (888) 529-4787, or by filling out this contact form. There is no cost or obligation to you. Kirby McInerney LLP is a New York-based law firm concentrating in securities, shareholder, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.
HOST // Robert Powell
Retirement Planning Event
More from Press Releases
NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling
The Supreme Court rules that previous congressional action forbidding states from legalizing sports betting was unconstitutional.
Walmart CEO: 'We Are Transforming Globally' With Flipkart
On its investor call on Wednesday morning, Walmart discusses the Flipkart deal.
March 24 Full-Day Course Offering: Professional Approach to Trading SPX
OptionsProfits, the CBOE, and Option Pit are hosting a class on March 24 that covers a wide variety of methods to trade the S&P 500.